Med2Date — Clinical Guidelines
Home Analgesia Safe Use of Opioids for Acute Pain

Safe Use of Opioids for Acute Pain

Last updated 1 Jun 2026 · Pain & analgesia

📋 Key Information Summary

📋
  • Opioids remain effective for moderate-to-severe acute pain but carry significant risks including respiratory depression, sedation, and dependence even with short courses.
  • Start with the lowest effective dose and titrate upward using validated pain scores (NRS 0–10); avoid fixed-dose prescribing without reassessment.
  • Respiratory rate (<8 breaths/min), sedation level (Pasero Opioid-Induced Sedation Scale), and oxygen saturation are the three mandatory monitoring parameters in hospital.
  • Community opioid prescriptions for acute pain should be limited to the shortest effective duration — typically ≤3 days; re-evaluate before extending.
  • Immediate-release formulations are preferred for acute pain; avoid modified-release opioids for acute presentations.
  • Multimodal analgesia (paracetamol, NSAIDs, regional techniques) should be the foundation, with opioids added only when non-opioid measures are insufficient.
  • Naloxone (Nyxoid® nasal spray) should be co-prescribed or available when opioids are dispensed for community use in patients at elevated overdose risk.
  • Patient education at discharge must cover safe storage, disposal (return unused medicines to pharmacy), driving restrictions, and signs of opioid toxicity.
  • Patients with renal impairment (eGFR <30 mL/min), hepatic impairment, obstructive sleep apnoea, or BMI >35 require dose reduction and enhanced monitoring.
  • Aboriginal and Torres Strait Islander Australians experience higher rates of opioid-related harm; culturally safe education and access to take-home naloxone are critical.
  • Codeine is now prescription-only in Australia (since February 2018); CYP2D6 ultra-rapid metabolisers are at particular risk of toxicity from standard codeine doses.
  • All opioid prescribing must be documented with indication, dose, duration, exit strategy, and patient consent — in accordance with NSQHS Standards and state opioid policies.

Introduction & Australian Epidemiology

Opioid analgesics — including morphine, oxycodone, tramadol, and codeine — remain indispensable agents for the management of moderate-to-severe acute pain when non-opioid strategies are inadequate. However, their use carries inherent risks of respiratory depression, excessive sedation, nausea, constipation, and the potential for misuse, even after short courses prescribed for legitimate medical indications.

In Australia, opioid-related harm represents a growing public health concern. According to the Australian Institute of Health and Welfare (AIHW), there were approximately 1,750 opioid-induced deaths in 2022, with the majority attributable to pharmaceutical opioids rather than heroin. The Therapeutic Goods Administration (TGA) reports that over 15 million opioid prescriptions are dispensed annually through the Pharmaceutical Benefits Scheme (PBS), with codeine-containing products historically among the most dispensed medications in community practice.

Since February 2018, all codeine-containing products have required a prescription in Australia, following a TGA decision based on evidence of widespread misuse, dependence, and deaths linked to over-the-counter codeine combinations. This regulatory change has shifted community opioid prescribing patterns and highlighted the need for enhanced clinician education around safe prescribing and patient counselling.

This guideline addresses safe opioid use for acute pain across community and hospital settings, covering dose titration, monitoring requirements, patient education, safe storage and disposal, and special population considerations — with particular attention to Aboriginal and Torres Strait Islander health equity.

🚨
Critical safety point: Opioid-related deaths in Australia most commonly involve respiratory depression during sleep. Patients prescribed opioids for community use must be counselled on the risks of concomitant benzodiazepines, alcohol, gabapentinoids, and sleeping medications, which synergistically increase ventilatory depression risk.

Community Opioid Use

Community prescribing of opioids for acute pain — typically following surgical procedures, acute musculoskeletal injuries, dental procedures, or renal colic — requires careful consideration of dose, duration, and patient-specific risk factors. The goal is to provide sufficient analgesia for functional recovery while minimising the risk of persistent use and harm.

Prescribing Principles

  • Duration: Prescribe the shortest effective course, generally ≤3 days for most acute pain presentations. Beyond 5 days, the risk of ongoing opioid use increases significantly (ref: Shah et al., MMWR, 2017).
  • Formulation: Use immediate-release (IR) formulations exclusively for acute pain. Modified-release (MR) and controlled-release (CR) opioids are contraindicated in the acute setting.
  • Quantity: Limit dispensed quantity to the anticipated need. For post-procedural pain, 10–15 tablets of an IR opioid with planned review is often sufficient.
  • Exit strategy: Document a plan for opioid cessation at the time of prescribing — including a weaning schedule if opioids are expected to be needed for >7 days.
  • Multimodal foundation: Prescribe regular paracetamol and/or NSAIDs alongside opioids, with the expectation that opioid dose will decrease as non-opioid analgesia takes effect.

Commonly Prescribed Opioids for Acute Community Pain

💊
Oxycodone IR
Endone® · OxyNorm® · Opioid agonist
Adult dose 5–10 mg PO every 4–6 hours PRN; max 40 mg/day for opioid-naive patients
Paediatric dose 0.1–0.2 mg/kg PO every 4–6 hours PRN (≥12 years with specialist advice for younger children)
Renal adjustment eGFR 10–50: reduce dose by 25–50%; eGFR <10: avoid or use with extreme caution
Hepatic adjustment Reduce dose by 50% in Child-Pugh B–C; increased half-life risk
PBS status ✔ PBS General Benefit
💊
Morphine IR
MS Contin® (MR) · Sevredol® (IR) · Opioid agonist
Adult dose 5–10 mg PO/SC every 4 hours PRN; start 2.5–5 mg in elderly
Paediatric dose 0.2–0.3 mg/kg PO every 4 hours PRN; 0.1 mg/kg IV/SC for acute severe pain
Renal adjustment Active metabolites (M6G) accumulate — reduce dose by 50% if eGFR <30; avoid in eGFR <10
Hepatic adjustment Reduce dose by 50% in significant hepatic impairment
PBS status ✔ PBS General Benefit
💊
Tramadol IR
Tramal® · Tramahexal® · Weak opioid + SNRI
Adult dose 50–100 mg PO every 4–6 hours PRN; max 400 mg/day
Paediatric dose 1–2 mg/kg PO every 4–6 hours (≥12 years; limited data <12 years)
Renal adjustment eGFR <30: extend interval to every 12 hours; max 200 mg/day
Hepatic adjustment Avoid in severe hepatic impairment; reduce dose in moderate impairment
PBS status ✔ PBS General Benefit
💊
Codeine IR
Panadeine® (combination) · Codeine phosphate · Prodrug opioid
Adult dose 30–60 mg PO every 4–6 hours PRN; max 240 mg/day
Paediatric dose Not recommended <12 years; 0.5–1 mg/kg PO every 4–6 hours in 12–18 years
Renal adjustment Reduce dose and extend interval; active metabolites accumulate
Hepatic adjustment Avoid in severe impairment — reduced conversion to active morphine metabolites
PBS status ✔ PBS General Benefit
⚠️
CYP2D6 ultra-rapid metabolisers: Approximately 5–10% of Caucasians and up to 29% of some North African/Ethiopian populations are CYP2D6 ultra-rapid metabolisers. Standard codeine doses can produce dangerously high morphine levels in these individuals, leading to respiratory depression and death. Consider avoiding codeine in patients with known ultra-rapid metaboliser status or when pharmacogenomic testing is available.

Co-Prescribing Naloxone for Community Use

Take-home naloxone (Nyxoid® 1.8 mg nasal spray) should be considered for co-prescription or dispensing alongside opioids in patients with risk factors for overdose. The PBS listing of Nyxoid® in 2022 has improved access significantly.

💡
Naloxone co-prescribing criteria — consider for any patient with:
  • History of substance use disorder (including alcohol)
  • Concurrent benzodiazepine, gabapentinoid, or sedative use
  • Dose ≥50 mg oral morphine equivalents (OME) per day
  • History of prior opioid overdose
  • Significant respiratory comorbidity (COPD, OSA, obesity hypoventilation)
  • Recent release from correctional facilities (loss of tolerance)

Hospital Monitoring

Hospital-based opioid administration for acute pain — whether patient-controlled analgesia (PCA), intravenous bolus, epidural, or oral — requires structured monitoring to detect early signs of ventilatory impairment and excessive sedation. Delayed recognition of respiratory depression is the leading cause of preventable opioid-related death in Australian hospitals.

Mandatory Monitoring Parameters

Parameter Frequency Alert Threshold Action
Respiratory rate Every 1 hour for first 24h after IV opioid; every 2h for oral opioids <8 breaths/min Hold opioid, stimulate patient, call MET/RRT if RR <6 or unresponsive
Sedation level (POSS) Every 1 hour for IV opioids; every 2h for oral POSS score ≥3 (very drowsy) Hold opioid, administer naloxone if unrousable (POSS 4–5)
Oxygen saturation (SpO₂) Continuous for IV PCA/infusions; intermittent for oral <94% (or <90% in chronic lung disease) Supplemental O₂, hold opioid, assess ventilation
Pain score (NRS 0–10) Every 4 hours minimum; 30 min post-dose for IV bolus NRS ≥7 despite maximal non-opioid therapy Review opioid dose, consider adjuncts, reassess diagnosis
Blood pressure Every 4 hours; continuous for PCA Systolic <90 mmHg or symptomatic hypotension Fluid bolus, hold opioid, assess for haemorrhage or sepsis

Pasero Opioid-Induced Sedation Scale (POSS)

POSS 1
Wide Awake
Patient alert, oriented, conversational. No sedation.
Action: Continue current regimen
POSS 2
Mildly Sedated
Occasionally drowsy but easily aroused, can follow commands.
Action: Continue; increase monitoring to every 30 min
POSS 3
Moderately Sedated
Frequently drowsy, arousable but drifts off to sleep mid-sentence.
Action: HOLD opioid, notify medical officer, monitor every 15 min
POSS 4
Excessively Sedated
Somnolent, minimal or no response to verbal stimulation.
Action: URGENT — naloxone, airway management, MET call
POSS 5
Unresponsive / Respiratory Depression
Cannot be aroused, respiratory rate <6 or apnoea, SpO₂ <90%.
Action: EMERGENCY — naloxone 0.4 mg IV stat, bag-mask ventilation, RRT/MET

Naloxone Administration in Hospital

💉
Naloxone (IV)
Narcan® · Opioid antagonist
Adult dose 40–100 mcg (0.04–0.1 mg) IV every 2–3 minutes titrated to respiratory effort; max 2 mg total initial dose
Paediatric dose 1–2 mcg/kg IV every 2–3 minutes; 0.1 mg/kg if <5 years or <20 kg
Onset / Duration IV onset 1–2 min; duration 20–60 min (shorter than most opioids — re-dose likely needed)
Key warning Titrate to respiratory effort, NOT full reversal — avoid precipitating acute withdrawal and pain crisis
PBS status ✔ PBS General Benefit
🚨
Critical — Naloxone titration principle: Administer naloxone in small increments (40–100 mcg IV) titrated to restoration of adequate respiratory effort — NOT full consciousness. Full reversal doses (0.4–2 mg IV push) can precipitate severe acute pain, sympathetic crisis, vomiting with aspiration risk, and pulmonary oedema. Always monitor for re-sedation as naloxone's duration (20–60 min) is shorter than most opioids.

High-Risk Patients Requiring Enhanced Monitoring

  • Continuous pulse oximetry and closer nursing observation (every 30 min) for patients with BMI >35, OSA, COPD, or heart failure
  • Patients aged ≥65 years: start at 50% of standard adult dose, increase monitoring frequency by 50%
  • Patients on concurrent benzodiazepines, gabapentinoids (pregabalin, gabapentin), antipsychotics, or sedating antihistamines
  • Post-anaesthesia patients: residual anaesthetic effects compound opioid respiratory depression for 24–48 hours
  • Patients with renal impairment: active metabolites of morphine (M6G, M3G) accumulate unpredictably
  • Consider continuous capnography (end-tidal CO₂ monitoring) for high-risk patients receiving IV PCA

Dose Titration

Appropriate dose titration is the cornerstone of safe opioid prescribing. The principle of "start low, go slow" must be balanced against the need to achieve adequate analgesia — untreated severe pain itself carries physiological consequences including tachycardia, hypertension, hyperglycaemia, immunosuppression, and delayed wound healing.

Oral Opioid Titration (Community and Ward)

1
Establish baseline pain
Assess pain using NRS (0–10). Ensure regular paracetamol ± NSAIDs are prescribed and administered. Document the baseline score.
2
Initiate low-dose opioid
Start with the lowest standard dose: oxycodone 5 mg PO, morphine 5 mg PO, or tramadol 50 mg PO. In elderly or renally impaired: halve the starting dose.
3
Reassess at 60 minutes (oral) or 15 minutes (IV)
Repeat NRS pain score and assess sedation (POSS). If POSS ≤2 and NRS remains ≥4, proceed to step 4. If POSS ≥3, hold and reassess.
4
Escalate dose incrementally
Increase the dose by 25–50% for each subsequent dose, reassessing at the same intervals. For example: oxycodone 5 mg → 7.5 mg → 10 mg PO PRN.
5
Cease titration when adequate
Stop titrating when NRS ≤3 and patient is comfortable with acceptable sedation (POSS 1–2). Document the effective dose and schedule. Begin transition to multimodal maintenance.

Intravenous Opioid Titration (ED / Acute Pain Service)

Opioid IV Bolus Titration Dose Interval Between Doses Onset Peak Effect
Morphine 2.5–5 mg IV every 15–20 min 15–20 min 5 min 15–20 min
Fentanyl 25–50 mcg IV every 5–10 min 5–10 min 1–2 min 5–10 min
Oxycodone IV 2–5 mg IV every 10–15 min 10–15 min 2–3 min 10–15 min
⚠️
Opioid equivalence and rotation: When switching between opioid routes or agents, use established equianalgesic ratios. Oral morphine 30 mg ≈ IV morphine 10 mg ≈ oral oxycodone 20 mg ≈ IV fentanyl 100 mcg ≈ oral tramadol 100 mg (approximate). When converting, reduce the calculated equianalgesic dose by 25–50% to account for incomplete cross-tolerance. Always verify calculations with a second clinician.

Patient-Controlled Analgesia (PCA)

PCA provides patient-directed titration within safety-guarded parameters. It is preferred over regular intramuscular injections and achieves more consistent analgesia with lower total opioid consumption.

Parameter Morphine PCA (standard adult) Fentanyl PCA (alternative)
Bolus dose 1 mg IV 15–25 mcg IV
Lockout interval 5–8 minutes 5–8 minutes
Maximum dose (1 hour) 10 mg 150 mcg
Background infusion Generally NOT recommended (increases respiratory depression risk) Generally NOT recommended
Elderly / renal dose 0.5 mg bolus, 8 min lockout, max 5 mg/hr 10 mcg bolus, 8 min lockout
🚨
Never allow patients to press their own PCA button during sleep or sedation. PCA demand should only be activated by the patient themselves. "By proxy" dosing (family members or nurses pressing the button on behalf of the patient) is a sentinel safety event risk and is explicitly contraindicated by the Australian and New Zealand College of Anaesthetists (ANZCA).

Opioid Dose Conversion Quick Reference

Oral morphine 30 mg
≈ IV morphine 10 mg
≈ Oral oxycodone 20 mg
Reduce 50% when rotating
IV morphine 10 mg
≈ IV fentanyl 100 mcg
≈ Transdermal fentanyl 12 mcg/hr
Patch has 12–24h onset delay
Oral morphine 30 mg/day
≈ Oral tramadol 100 mg
Ceiling: tramadol 400 mg/day
Not directly interchangeable at high doses

Patient Education

Patient education is a critical safety intervention at every point of opioid prescribing — at initiation, during use, and at discharge. Evidence from the Australian Commission on Safety and Quality in Health Care (ACSQHC) indicates that structured patient education reduces opioid-related adverse events by up to 30% and decreases the likelihood of persistent opioid use after acute pain episodes.

Key Educational Messages (Discharge Checklist)

1
Purpose and duration
"This medicine is for short-term pain relief. Use it only for as long as your doctor has prescribed. If your pain continues beyond the prescribed duration, see your GP — do NOT take leftover tablets or request refills without medical review."
2
Take as directed
"Take the dose prescribed, at the intervals stated. Do not increase the dose or frequency on your own, even if pain is severe. If the medicine is not controlling your pain, contact your doctor."
3
Do not mix with sedatives
"Do not drink alcohol, take sleeping tablets, benzodiazepines (e.g., diazepam), or antihistamines while taking opioids. These combinations can dangerously slow your breathing."
4
Driving and work
"Do not drive, operate heavy machinery, or perform safety-critical tasks while taking opioids. Opioids impair reaction time and judgment. This is a legal requirement in all Australian states and territories."
5
Safe storage
"Store this medicine in a locked cabinet or secure location, out of reach of children, visitors, and household members. Opioid poisoning is a leading cause of childhood hospitalisation in Australia."
6
Safe disposal
"Return all unused or expired opioids to your local pharmacy for safe destruction. Do not flush them down the toilet or place them in household rubbish. The RUM Project (Return Unwanted Medicines) is a free service."
7
Recognise overdose signs
"If you or someone you live with becomes very drowsy, has slow or noisy breathing, has blue lips, or cannot be woken — call 000 immediately. If naloxone (Nyxoid®) has been provided, use it and call 000."
📘
Consumer Medicine Information (CMI): Provide the CMI leaflet for each opioid dispensed. CMIs are available from the NPS MedicineWise website (nps.org.au) and must accompany all PBS prescriptions. Encourage patients and carers to read the CMI before commencing treatment.

Safe Disposal — Return Unwanted Medicines (RUM) Project

The RUM Project, administered by the National Prescribing Service (NPS MedicineWise), provides a free, environmentally safe mechanism for returning unused medicines to community pharmacies across Australia. All Schedule 8 (controlled) medicines, including opioids, should be returned through this programme. Pharmacies are required to accept returned opioids and arrange destruction through appropriate pharmaceutical waste channels.

  • Patients should be instructed to return opioids as soon as they are no longer needed — do not stockpile "just in case"
  • Returned opioids are weighed and documented; pharmacies must maintain records in compliance with state health department requirements
  • Medicines should be returned in their original packaging where possible to facilitate identification
  • Patients in rural and remote areas who cannot easily access a pharmacy should contact their local Aboriginal Medical Service, hospital, or community health centre

Documenting the Educational Encounter

In accordance with NSQHS Standard 4 (Medication Safety), the following should be documented in the patient's medical record at each opioid prescribing encounter:

  • Indication for opioid use (specific pain diagnosis)
  • Opioid name, dose, route, frequency, and planned duration
  • Exit strategy — how and when opioids will be ceased or weaned
  • Patient (or carer) verbal understanding of key safety messages confirmed
  • Take-home naloxone offered/prescribed (if risk criteria met) — document if declined
  • Patient's PBS opioid history reviewed (available via My Health Record or state real-time prescription monitoring — SafeScript VIC, SafeScript NSW, QScript QLD, ScriptCheckWA, NT TPOMS)

Special Populations

👶

Paediatrics

Morphine 0.1–0.2 mg/kg IV/SC every 2–4 hours; 0.2–0.3 mg/kg PO every 4 hours. Neonates (especially preterm): significantly reduced clearance — use neonatal dosing guidelines and continuous monitoring.
Oxycodone 0.1–0.2 mg/kg PO every 4–6 hours for children ≥1 year. Limited data in infants <6 months.
Codeine Contraindicated <12 years (TGA, 2015). Avoid in 12–18 years after tonsillectomy/adenoidectomy due to fatal outcomes in CYP2D6 ultra-rapid metabolisers. Use morphine or oxycodone instead.
Fentanyl intranasal 1.5 mcg/kg intranasal for procedural pain in ED. Rapid onset (5 min). Useful for fracture reduction and wound management.
Monitoring: Continuous pulse oximetry mandatory for all IV opioids in children. Paediatric Modified Early Warning Score (PEWS) to be recorded alongside pain scores. Age-appropriate pain assessment tools required (FLACC <3 years, Wong-Baker FACES 3–7 years, NRS ≥8 years).
👴

Elderly (≥65 Years)

All opioids Start at 25–50% of standard adult dose. Reduced volume of distribution, decreased hepatic metabolism, and reduced renal clearance increase drug exposure and duration of effect.
Tramadol Increased seizure risk and serotonin syndrome risk — use with caution, max 200 mg/day. Avoid in patients on SSRIs, SNRIs, or MAOIs.
Morphine Active metabolite M6G accumulates with declining renal function — prefer oxycodone or fentanyl if eGFR <30.
Additional risks: Falls risk increased 2–3× in the first 2 weeks of opioid use. Delirium precipitated by opioids is common — screen with 4AT. Constipation prophylaxis with regular oral laxatives (macrogol ± senna) mandatory from the first dose.
🫘

Renal Impairment

Morphine Avoid if eGFR <30. Active metabolite M6G accumulates, causing prolonged sedation and respiratory depression. If unavoidable, reduce dose by 50–75% and monitor extremely closely.
Oxycodone Reduce dose by 25–50% if eGFR 10–50; avoid if eGFR <10 unless specialist advice. Less active metabolite accumulation than morphine.
Fentanyl Preferred in severe renal impairment (eGFR <15) — no active metabolites. Dose reduction may still be needed due to altered protein binding. Use IV titration in hospital.
Buprenorphine Transdermal buprenorphine (Norspan®) has minimal renal metabolite accumulation — a reasonable option for moderate-severe CKD with ongoing pain.
🫁

Hepatic Impairment

All opioids Reduced hepatic clearance prolongs half-life. Reduce dose by 50% in Child-Pugh B; avoid or use with extreme caution in Child-Pugh C. Paracetamol ceiling dose: 2 g/day (not 4 g/day) in chronic liver disease.
Tramadol Avoid in severe hepatic impairment — both opioid and serotonergic effects are prolonged. Seizure threshold further lowered.
Encephalopathy risk: Opioids can precipitate or worsen hepatic encephalopathy. Use lowest effective dose and monitor mental state closely with each dose. Avoid morphine in cirrhotic patients due to impaired first-pass metabolism.
🛡️

Immunocompromised

All opioids Opioids have immunosuppressive effects (reduced NK cell activity, T-cell proliferation). In patients with active sepsis, neutropenic fever, or post-transplant, use the shortest effective course and prioritise non-opioid and regional analgesia.
Morphine Most immunosuppressive of commonly used opioids. Consider fentanyl or oxycodone in neutropenic patients where feasible.
Pain assessment: Immunocompromised patients may have atypical pain presentations. Consider that pain atypical for the diagnosis may indicate opportunistic infection or treatment complication — investigate before escalating opioids.
🤰

Pregnancy & Breastfeeding

Codeine Avoid — especially in third trimester and during breastfeeding. Neonatal respiratory depression and neonatal abstinence syndrome risk. CYP2D6 ultra-rapid metaboliser mothers produce high morphine levels in breast milk.
Morphine / Oxycodone Use only when clearly indicated and non-opioid measures are insufficient. Short courses acceptable. Monitor neonate for respiratory depression and withdrawal if used in the third trimester.
Tramadol Avoid in third trimester and breastfeeding. Neonatal withdrawal and seizures reported.
Teratogenicity: No confirmed major teratogenic risk with short-course opioids in first trimester, but emerging data suggest a small increased risk of cardiac defects with prolonged use. Use only when benefit clearly outweighs risk.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of opioid-related harm, including higher rates of opioid dispensing, opioid-related hospitalisations, and opioid-induced deaths compared to non-Indigenous Australians. The AIHW reports that Indigenous Australians are approximately 1.5 times more likely to be dispensed an opioid and 2 times more likely to die from an opioid overdose than their non-Indigenous counterparts. These disparities are driven by a complex interplay of higher chronic disease burden (particularly musculoskeletal conditions and chronic pain), reduced access to multimodal pain services, socio-economic disadvantage, intergenerational trauma, and systemic barriers to culturally safe healthcare.

Higher chronic pain prevalence
Aboriginal and Torres Strait Islander adults report chronic pain at approximately twice the rate of non-Indigenous Australians (AIHW, 2023). Chronic musculoskeletal conditions, dental disease, and injury contribute to sustained opioid demand. Access to non-pharmacological pain management — including physiotherapy, psychology, and specialist pain clinics — is severely limited in remote and very remote communities.
Geographic access barriers
In remote and very remote communities, primary healthcare is predominantly delivered by Aboriginal Community Controlled Health Organisations (ACCHOs) and remote area nurses. Specialist pain services, addiction medicine, and mental health services may be hundreds of kilometres away. Telehealth is increasingly available but cannot replace the need for local, culturally safe, face-to-face opioid counselling and monitoring.
Take-home naloxone access
Take-home naloxone programmes are critical in communities where opioid-related mortality is elevated. The PBS listing of Nyxoid® (naloxone nasal spray) has improved access, but distribution through ACCHOs, pharmacies in remote areas, and community health workers remains inconsistent. Training community members in naloxone use is a high-priority harm reduction strategy endorsed by NACCHO and the Australian Injecting and Illicit Drug Users League (AIVL).
Cultural safety in prescribing
Healthcare providers must deliver opioid education in a culturally safe manner, acknowledging the historical context of government control over Aboriginal lives and medicines. Language-appropriate educational materials, Aboriginal Health Practitioners as key educators, and avoidance of stigmatising language ("drug-seeker," "addict") are essential. The NACCHO position statement on pain management emphasises self-determination and community-led approaches.
Real-time prescription monitoring (RTPM)
State-based real-time prescription monitoring systems (SafeScript, QScript, ScriptCheckWA, NT TPOMS) have varying levels of implementation in remote Indigenous communities. In the Northern Territory, the Territory Patient Opioid Monitoring System (TPOMS) is the primary tool, but workforce training and system access in remote clinics remain inconsistent. Clinicians must actively check RTPM before any opioid prescription, where available.
Safe storage and disposal challenges
In many remote communities, secure medication storage is limited by housing conditions, communal living arrangements, and the absence of local pharmacy services for medication return. Community-controlled health services should implement home medication reviews and safe storage interventions as part of chronic disease management programmes. Fridge-locked boxes and lockable storage containers should be provided to all patients dispensed opioids in remote settings.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) report 2023. Canberra: AIHW; 2023. Available from: aihw.gov.au.
  2. 2. Australian Commission on Safety and Quality in Health Care (ACSQHC). Medication Safety: National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
  3. 3. Shah A, Hayes CJ, Martin BC. Characteristics of initial prescription episodes and likelihood of long-term opioid use — United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66(10):265–269.
  4. 4. Pasero C, McCaffery M. Pain Assessment and Pharmacologic Management. St Louis: Mosby Elsevier; 2011. (Pasero Opioid-Induced Sedation Scale — POSS).
  5. 5. Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine (ANZCA FPM). Acute Pain Management: Scientific Evidence. 5th ed. Melbourne: ANZCA; 2020.
  6. 6. Therapeutic Goods Administration (TGA). Changes to codeine access — Information for consumers, health professionals and sponsors. Canberra: Department of Health; 2018.
  7. 7. NPS MedicineWise. Return Unwanted Medicines (RUM) Project. Sydney: NPS MedicineWise; 2024. Available from: returnmed.com.au.
  8. 8. National Aboriginal Community Controlled Health Organisation (NACCHO). Position Statement: Pain Management and Opioid Use in Aboriginal and Torres Strait Islander Communities. Canberra: NACCHO; 2022.
  9. 9. Paulozzi LJ, Strickler GK, Kreiner PW, Koris CM. Controlled substance prescribing patterns — Prescription Behavior Surveillance System, eight states, 2013. MMWR Surveill Summ. 2015;64(9):1–14.
  10. 10. Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R. The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. Pharmacoepidemiol Drug Saf. 2016;25(5):521–538.
  11. 11. Schug SA, Palmer GM, Scott DA, Halliwell R, Trinca J. Acute pain management: scientific evidence, fourth edition, 2015. Med J Aust. 2016;204(8):315–317. (ANZCA/FPM).
  12. 12. Royal Australian College of General Practitioners (RACGP). Prescribing drugs of dependence in general practice, Part B — Opioids. Melbourne: RACGP; 2022.
  13. 13. Larance B, Degenhardt L, Grebely J, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments for opioid use disorder among people who inject drugs in Australia. Int J Drug Policy. 2020;77:102668.
  14. 14. Victoria Department of Health. SafeScript: Real-Time Prescription Monitoring Program. Melbourne: Victorian Government; 2023. Available from: health.vic.gov.au/safescript.
  15. 15. Crabtree A, Rose C, Chai M, et al. Opioid prescribing in a remote Aboriginal community in the Northern Territory: a retrospective audit. Aust J Rural Health. 2021;29(4):543–551.
for PBS scripts. Utilise ACCHS pharmacies and Remote Area Aboriginal Health Worker programs for medication supply in remote areas. Avoid initiating benzodiazepines; support holistic pain management including community-based exercise programs.
Preventive health
Promote bone health: encourage vitamin D supplementation (1000 IU daily in deficient individuals), smoking cessation support, reduction of alcohol intake, and weight-bearing exercise. MBS Item 715 health checks provide a structured opportunity to assess bone health, screen for osteoporosis risk factors, and discuss musculoskeletal health in a culturally safe context.

Quick Reference: Differential Diagnosis at a Glance

Costovertebral dysfunction
Paracetamol ± NSAID; manual therapy
2–6 weeks
Provocable on palpation; no red flags
Thoracic compression fracture
Paracetamol; ± calcitonin; DXA + osteoporosis Rx
6–12 weeks healing
Elderly; osteoporosis; acute onset
ACS (posterior MI)
Aspirin 300 mg, GTN, heparin; urgent PCI
Time-critical
ECG, troponin; CV risk factors
Aortic dissection
IV labetalol; urgent CT aortogram; surgery (Type A)
Time-critical
Tearing pain; BP differential >20 mmHg
Vertebral osteomyelitis
IV antibiotics (vancomycin + ceftriaxone initially); ID consult
6 weeks IV antibiotics
Fever, elevated CRP, IV drug use
Biliary colic / cholecystitis
Paracetamol ± morphine; lap cholecystectomy
Surgical within 72 h (cholecystitis)
RUQ/infrascapular; post-prandial; RUQ US

📚 References

  1. 1. Briggs AM, Smith AJ, Straker LM, Bragge P. Thoracic spine pain in the general population: prevalence, incidence and associated factors in children, adolescents and adults. A systematic review. BMC Musculoskelet Disord. 2009;10:77.
  2. 2. National Health and Medical Research Council (NHMRC). Evidence-based management of acute musculoskeletal pain. Canberra: NHMRC; 2003 (updated 2020).
  3. 3. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Summary report 2023. Canberra: AIHW; 2023.
  4. 4. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? JAMA. 1992;268(6):760–765.
  5. 5. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Europ Spine J. 2018;27(1):60–75.
  6. 6. Erwin WM, Jackson PC, Homonko DA. Innervation of the human costovertebral joint: implications for clinical back pain syndromes. J Manipulative Physiol Ther. 2000;23(6):395–403.
  7. 7. Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice. 9th edn. Melbourne: RACGP; 2018 (updated 2023).
  8. 8. Hirsch JA, Singh V, Falco FJE, et al. Thoracic facet joint interventions. Pain Physician. 2016;19(4):E581–E593.
  9. 9. Erwin WM, Jackson PC. The costovertebral joint: anatomy, biomechanics, and clinical significance in thoracic back pain syndromes. J Can Chiropr Assoc. 2003;47(2):112–120.
  10. 10. Strayer RJ, Gunnerson JM, Brown LH, et al. Aortic dissection: clinical features, diagnosis, and management. Aust Crit Care. 2019;32(2):144–153.
  11. 11. Ombregt L. A system of orthopaedic medicine. 3rd edn. Edinburgh: Churchill Livingstone Elsevier; 2013. Chapter 18: Thoracic spine.
  12. 12. Lin CC, Chen KH, Li DM, et al. Characteristics and outcomes of patients presenting with thoracic back pain to the emergency department. Emerg Med Australas. 2020;32(5):805–811.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).